Skip to main content
Log in

Influence of physical exercise on the pharmacokinetics of propranolol

  • Short Communications
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The pharmacokinetics of propranolol after oral and intravenous administration was studied at rest and on an exercise day in 8 healthy subjects. On the exercise day the subjects performed physical exercise for 7 h, consisting of bicycle ergometer exercise at 50% of maximal work capacity and outdoor walking. Propranolol (80 mg p.o., or 0.2 mg/kg body weight i.v.) was administered 30 min before the start of the exercise. After oral administration the terminal phase halflife, (t1/2β) and area under the curve (AUC) were both significantly reduced on the exercise day compared to the rest day. The bioavailability of propranolol was reduced by prolonged physical exercise and plasma levels of propranolol were about 30% lower at the end of the exercise day than at the end of the rest day. After intravenous administration, t1/2β was also reduced on the exercise day as compared to the rest day. AUC, clearance and volume of distribution did not differ on the two days. On the other hand, indocyanine green (ICG) clearance was significantly reduced during the bicycle ergometry periods on the exercise day. The combination of reduced ICG clearance, suggesting a reduction in hepatic blood flow, and a decreased t1/2β and unchanged clearance of propranolol on the exercise day was unexpected.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Rowell LB, Blackmon JR, Bruce RA (1964) Indocyanine green clearance and estimated hepatic blood flow during mild to maximal exercise in upright man. J Clin Invest 43: 1677–1690

    Google Scholar 

  2. Swartz RD, Siddel FR, Cucinell SA (1973) Effects of physical stress on the disposition of drugs eliminated by the liver in man. J Pharmacol Exp Ther 188: 1–7

    Google Scholar 

  3. Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377–390

    Google Scholar 

  4. Sweeney GD (1981) Drugs-some basic concepts. Med Sci Sports Exerc 13: 247–251

    Google Scholar 

  5. Evans GH, Shand DG (1973) Disposition of propranolol VI. Clin Pharmacol Ther 14: 494–500

    Google Scholar 

  6. Mooij JMV, Böhm R, Petri H, Van Kemenade J, Rahn KH (1986) A comparison of the effects of verapamil and propranolol on submaximal exercise tolerance in patients with essential hypertension. Clin Pharmacol Ther (in press)

  7. Svensson CK, Edwards DJ, Mauriello PM, Barde SH, Foster AC, Lanc RA, Middleton E, Lalka D (1983) Effect of food on hepatic blood flow: Implications in the “food effect” phenomenon. Clin Pharmacol Ther 34: 316–323

    Google Scholar 

  8. Kornhauser DM, Wood AJJ, Vestal RE, Wilkinson GR, Branch RA, Shand DG (1978) Biological determinants of propranolol disposition in man. Clin Pharmacol Ther 23: 165–174

    Google Scholar 

  9. Johnsson G, Regårdh CG (1976) Clinical pharmacokinetics of beta-adrenoceptor blocking drugs. Clin Pharmacokinet 1: 233–263

    Google Scholar 

  10. Aslaksen A, Aanderud L (1980) Drug absorption during physical exercise. Br J Clin Pharmacol 10: 383–385

    Google Scholar 

  11. Rosenbloom D, Sutton JR (1985) Drugs and exercise. Med Clin North Am 69: 177–187

    Google Scholar 

  12. Nies AS, Shand DG, Wilkinson GR (1976) Altered hepatic blood flow and drug disposition. Clin Pharmacokinet 1: 135–155

    Google Scholar 

  13. Rowell LB (1974) Human cardiovascular adjustment to exercise and thermal stress. Physiol Rev 54: 75–159

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arends, B.G., Böhm, R.O.B., van Kemenade, J.E. et al. Influence of physical exercise on the pharmacokinetics of propranolol. Eur J Clin Pharmacol 31, 375–377 (1986). https://doi.org/10.1007/BF00981142

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00981142

Key words

Navigation